Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INJECTAPAP vs ADEFOVIR DIPIVOXIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.
Management of mild to moderate pain,Reduction of fever
Treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.,Treatment of chronic hepatitis B in pediatric patients aged 12 years and older.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
10 mg orally once daily on an empty stomach.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Terminal elimination half-life is 7.5 hours (range 5–10 h); clinically, supports once-daily dosing with dose adjustment for renal impairment.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Adefovir dipivoxil is rapidly converted to adefovir by esterases. Adefovir is not significantly metabolized; it is eliminated renally by a combination of glomerular filtration and active tubular secretion. No CYP450-mediated metabolism.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
Renal (90% as unchanged drug via active tubular secretion); biliary/fecal (<5%)
10-25% bound to albumin at therapeutic concentrations.
≤4% (low binding; negligible affinity for serum proteins)
0.8-1.0 L/kg; suggests distribution into total body water.
0.4 L/kg (392 L in adults); indicates extensive tissue distribution (including liver).
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
Oral: 59% (range 40–70%); prodrug adefovir dipivoxil is rapidly converted to adefovir.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
Cr Cl ≥50 m L/min: 10 mg every 24 hours; Cr Cl 30-49 m L/min: 10 mg every 48 hours; Cr Cl 10-29 m L/min: 10 mg every 72 hours; Hemodialysis: 10 mg every 7 days after dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
No adjustment required for mild-moderate hepatic impairment (Child-Pugh A or B). Not studied in severe (Child-Pugh C).
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Approved for age ≥12 years: 10 mg orally once daily. For age <12 years, use is not established.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
Monitor renal function; adjust dose based on Cr Cl. No specific dose adjustment solely for age.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
WARNING: SEVERE ACUTE EXACERBATION OF HEPATITIS B, NEPHROTOXICITY, HIV RESISTANCE, and LACTIC ACIDOSIS/HEPATOMEGALY WITH STEATOSIS. See full prescribing information for complete boxed warning.
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Severe acute exacerbation of hepatitis B upon discontinuation of therapy,Nephrotoxicity: monitor renal function, especially in patients at risk or with pre-existing renal impairment,HIV resistance: test for HIV before initiation in patients with unknown HIV status,Lactic acidosis and severe hepatomegaly with steatosis,Use with caution in elderly, renal impairment, or concomitant nephrotoxic agents
Hypersensitivity to acetaminophen or any component of the formulation
Hypersensitivity to adefovir dipivoxil or any component of the formulation
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
No clinically significant food interactions; can be taken with or without food. Avoid high-fat meals if gastrointestinal intolerance occurs.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Adefovir dipivoxil is an FDA Pregnancy Category C drug. Animal studies have shown teratogenicity (malformations, embryo-fetal toxicity) at doses 23 times the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. In first trimester, risk cannot be excluded; use only if benefit outweighs risk. In second and third trimesters, potential for fetal harm exists; consider alternative therapy.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
It is unknown whether adefovir is excreted in human breast milk. Animal studies indicate it is present in rat milk. The M/P ratio is not established. Given the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy or for 2 weeks after last dose.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Pregnancy may increase renal clearance; however, specific pharmacokinetic data are lacking. Dose adjustment is not routinely recommended but may be necessary if renal function changes. Use standard dose of 10 mg once daily with monitoring of renal function and HBV DNA levels.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Monitor renal function closely; dose adjust for Cr Cl <50 m L/min. Check LFTs and HBV DNA every 3 months. Avoid in decompensated cirrhosis. HIV co-infected patients require concomitant antiretroviral therapy due to risk of HIV resistance. Prolonged therapy may lead to adefovir-resistant HBV mutations (rt A181V/T, rt N236T).
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
Take with or without food at the same time daily.,Do not stop taking without consulting your doctor; stopping may cause severe hepatitis flare.,Report any signs of kidney problems (decreased urination, swelling) or lactic acidosis (unusual muscle pain, trouble breathing).,Regular blood tests are required to monitor liver and kidney function.,Use effective contraception during treatment if you or your partner can become pregnant.,Avoid alcohol and other medications that can damage the liver or kidneys without medical advice.
No interactions on record
"Coadministration of adefovir dipivoxil and tenofovir disoproxil may reduce the antiviral efficacy of tenofovir by competing for renal tubular secretion via organic anion transporters (OATs) and potentially intracellular phosphorylation pathways. This competition can decrease tenofovir's intracellular active metabolite concentrations, leading to suboptimal viral suppression and increased risk of treatment failure in patients with chronic hepatitis B."
"The serum concentration of Teriflunomide can be increased when it is combined with Adefovir dipivoxil."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INJECTAPAP vs ADEFOVIR DIPIVOXIL, answered by our medical review team.
INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. ADEFOVIR DIPIVOXIL is a Antiviral that works by Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INJECTAPAP and ADEFOVIR DIPIVOXIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. The standard adult dose of ADEFOVIR DIPIVOXIL is: 10 mg orally once daily on an empty stomach.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INJECTAPAP and ADEFOVIR DIPIVOXIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. ADEFOVIR DIPIVOXIL is classified as Category C. Adefovir dipivoxil is an FDA Pregnancy Category C drug. Animal studies have shown teratogenicity (malformations, embryo-fetal toxicity) at doses 23 times the human therapeutic dose. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.